As always, a very nice synopsis but with a few glaring flaws which I know you are aware of.
Regen is not trading so the basis of what it will be worth is anyone's guess ( I acknowledge you have stated that market forces will determine that). And if we take the $1 to $.01 Regen to BMSN as a working hypothesis, Regen is now valued at...drum roll please....
a whopping .29 Cents.
No one knows what the demand for Regen will be and with how BMSN trades, it won't be great since the only demand for BMSN shares is from a zealous few.
The bottom line here, there is no demand for BMSN shares and why it trades for a measly .0029. Pathetic for a stock with so much potential.
So how does Regen, once it starts trading, create demand? Public knowledge of what is offers in its pipeline.
How will King Koos aka The Secretive Sailing King, do this?
Well first, Hemaxcellerate needs to get that illusive FDA approval with orphan status. We still wait for that.
Second, the dCellVax IND needs to be submitted. We still wait for that.
Third, Regen needs to be listed on a major trading board if it wants to be taken seriously. Odds of that happening are slim to none. Why not you ask? Regen doesn't have the listing requirements to do so.
Fourth, the legit investment community needs to know about these drugs. Not sure how Koos is going to get the word out. Hopefully he doesn't use the same folks that CHTP used. But even then, would any legit investment company invest in an OTC company lead by someone with a very sketchy investment/managerial past?
Fifth, more peer reviewed work in scientific journals. Creating a genuine interest in the medical field can be quite helpful.
Sixth, a major pharmaceutical or a well established partner (grants included) shows up to help fund trials. This would be the most desirable.
Koos has a brother who is a doctor at UCLA. I have no idea if he has any connections in helping his brother. I do know they had worked together in the past but maybe his own brother decided enough was enough and went back to focus on his practice instead of business.
Now, it's easy to dream up scenarios and plan for parties, but it's a whole other matter in actually developing procedures that actually work in humans. I think only a few on here understand that. There is a battle field of fallen biotechs that were claimed by investors to have billion dollar drugs.
Clinical trials run by The Dragon mother (FDA) are her three dragons (ie three phases of clinical trials) burn into oblivion the vast majority drug/procedures.
BMSN is still a far away in commercializing. The big first hurdle still hasn't been cleared. That being FDA approval to initiate P1 trials.
The irrational exuberance on here is quite amusing. My take has always been let's wait until BMSN actually gets that approval to start P1 and see how that goes.
But the harsh reality is the odds are against this company as it usually is with many BIOTECHS.
I just don't think many on here truly understand the nature of biotechs.
And hopefully we'll start to see a more rational approach to posting on here.
AI
